Ohr Pharma appoints new director
This article was originally published in Scrip
New York-based Ohr Pharmaceutical, which is currently developing treatments for the wet form of age-related macular degeneration and for cancer cachexia, has appointed Dr Thomas Riedhammer to its board of directors. Most recently, Dr Riedhammer was chair of Sirion Therapeutics. Prior to Sirion, he was chief operating officer at Presby, a medical device company which develops treatments for eye disorders.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.